We are live on ! Find out more
EAM

Eventide Asset Management Portfolio holdings

AUM $7.48B
1-Year Est. Return 104.76%
This Fund
S&P 500
This Quarter Est. Return
+2.73%
1 Year Est. Return
+104.76%
3 Year Est. Return
+313.12%
5 Year Est. Return
+388.67%
10 Year Est. Return
+3,437.54%
AUM
$7.58B
AUM Growth
+$139M
Cap. Flow
+$157M
Cap. Flow %
2.07%
Top 10 Hldgs %
25.49%
Holding
165
New
14
Increased
52
Reduced
27
Closed
13

Top Buys

Rank Stock Value
1
DICE
DICE Therapeutics, Inc. Common Stock
DICE
+$63.7M
2
FIVN icon
FIVE9
FIVN
+$52.6M
3
XMTR icon
Xometry
XMTR
+$50.4M
4
GLBE icon
Global E Online
GLBE
+$32.3M
5
FVRR icon
Fiverr
FVRR
+$31.6M

Top Sells

Rank Stock Value
1
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$83.1M
2
TRIL
Trillium Therapeutics Inc.
TRIL
+$50M
3
CLDX icon
Celldex Therapeutics
CLDX
+$46M
4
BBIO icon
BridgeBio Pharma
BBIO
+$43.4M
5
RNG icon
RingCentral
RNG
+$39.4M

Sector Composition

Rank Sector Weight
1 Healthcare 35.8%
2 Technology 30.11%
3 Industrials 12.97%
4 Consumer Discretionary 7.19%
5 Communication Services 4.5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BCYC
51
Bicycle Therapeutics
BCYC
$257M
$48.4M 0.64%
1,163,471
– –
ANNX icon
52
Annexon
ANNX
$743M
$47.1M 0.62%
2,531,628
+122,462
+5% +$2.48M
NCNO icon
53
nCino
NCNO
$2.32B
$47.1M 0.62%
662,500
– –
SMAR
54
DELISTED
Smartsheet Inc.
SMAR
$45.7M 0.6%
664,131
-32,000
-5% -$2.35M
BEP icon
55
Brookfield Renewable
BEP
$8.65B
$45.6M 0.6%
1,236,000
– –
STRO icon
56
Sutro Biopharma
STRO
$275M
$44.8M 0.59%
237,098
– –
NOVT icon
57
Novanta
NOVT
$5.23B
$43.3M 0.57%
280,000
– –
IMVT icon
58
Immunovant
IMVT
$7.57B
$43M 0.57%
4,950,000
+1,579,006
+47% +$14.2M
XMTR icon
59
Xometry
XMTR
$5.02B
$42.8M 0.56%
742,802
+727,802
+4,852% +$50.4M
VRSK icon
60
Verisk Analytics
VRSK
$23.4B
$42.7M 0.56%
213,000
– –
CWEN icon
61
Clearway Energy Class C
CWEN
$6.14B
$42.5M 0.56%
1,402,600
+99,200
+8% +$2.95M
MDB icon
62
MongoDB
MDB
$30.4B
$42.1M 0.56%
89,355
– –
COMP icon
63
Compass
COMP
$7.95B
$40.6M 0.54%
3,065,563
+1,043,532
+52% +$15M
TPTX
64
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$38.4M 0.51%
578,000
– –
MPWR icon
65
Monolithic Power Systems
MPWR
$56.1B
$37.5M 0.5%
77,459
– –
PLRX icon
66
Pliant Therapeutics
PLRX
$69.4M
$36.9M 0.49%
2,183,238
-288,654
-12% -$6.13M
BPMC
67
DELISTED
Blueprint Medicines
BPMC
$36.6M 0.48%
356,000
-105,712
-23% -$9.84M
NRIX icon
68
Nurix Therapeutics
NRIX
$2.58B
$36M 0.47%
1,200,000
– –
ADCT icon
69
ADC Therapeutics
ADCT
$139M
$35.6M 0.47%
1,311,990
– –
BEPC icon
70
Brookfield Renewable
BEPC
$5.39B
$35.6M 0.47%
916,319
+7,400
+0.8% +$310K
ZNTL icon
71
Zentalis Pharmaceuticals
ZNTL
$296M
$35.3M 0.46%
529,000
+108,600
+26% +$6.26M
RGEN icon
72
Repligen
RGEN
$9.86B
$34.4M 0.45%
119,000
– –
GLBE icon
73
Global E Online
GLBE
$6.13B
$34.3M 0.45%
+478,198
New +$32.3M
RNG icon
74
RingCentral
RNG
$6.05B
$32M 0.42%
147,308
-155,300
-51% -$39.4M
CGEM icon
75
Cullinan Oncology
CGEM
$1.32B
$31.7M 0.42%
1,440,145
– –
1 2
3
4 5

Similar funds

S
SignatureFD Atlanta, Georgia $7.49B AUM 24.82% 1-Year Est. Return
CCM
Check Capital Management Costa Mesa, California $7.52B AUM 15.3% 1-Year Est. Return
O
Ossiam Paris, France $7.54B AUM 50.81% 1-Year Est. Return
HI
Harbour Investments Madison, Wisconsin $7.43B AUM 24.49% 1-Year Est. Return
HPC
HM Payson & Co Portland, Maine $7.54B AUM 31.34% 1-Year Est. Return
FPP
Findlay Park Partners London, United Kingdom $7.41B AUM 26.32% 1-Year Est. Return
RIG
RiverFront Investment Group Richmond, Virginia $7.56B AUM 23.82% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $7.56B AUM 44.87% 1-Year Est. Return

Eventide Asset Management's Q3 2021 Portfolio in Review

As of Q3 2021, Eventide Asset Management held 165 positions worth $7.58B, up 1.9% from $7.44B the previous quarter. Its ten largest holdings account for 25% of the portfolio.

Eventide Asset Management's Q3 2021 filing shows 14 new, 52 increased, 27 reduced and 13 closed positions. Its largest new stake was DICE Therapeutics, Inc. Common Stock: 1,871,612 shares worth $59.2M. The largest sale was Biohaven Pharmaceutical Holding Company Ltd., an estimated $83.1M.

By sector, the portfolio is most concentrated in Healthcare at 36% of assets, down from 37% a quarter earlier, followed by Technology and Industrials.

  • Eventide Asset Management's largest Q3 2021 buy was DICE Therapeutics, Inc. Common Stock: 1,871,612 shares worth $59.2M.
  • Eventide Asset Management added most to FIVE9 in Q3 2021, an estimated $52.6M increase.
  • Eventide Asset Management's biggest Q3 2021 reduction was Biohaven Pharmaceutical Holding Company Ltd., cutting an estimated $83.1M.
  • Eventide Asset Management fully exited BridgeBio Pharma in Q3 2021, selling an estimated $43.4M.
  • Eventide Asset Management's ten largest holdings make up 25% of its $7.58B portfolio in Q3 2021.
  • Eventide Asset Management opened 14 new positions and closed 13 in Q3 2021.
  • Eventide Asset Management's portfolio value rose 1.9% quarter-over-quarter to $7.58B.

Based on Eventide Asset Management's 13F filing for Q3 2021, filed 15 Nov 2021.